The mechanism responsible for the reduction or elimination of LMTM effects in mice pretreated with AD-approved drugs appears to be part of a general homeostatic downregulation occurring in many neuronal systems in the brain that compensates for the activating effects of cholinesterase inhibitors and memantine. Here, BCHE is linked to Alzheimer disease.